Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125425 | 0.86 | P2RX7 (0.52) | P2RX7RXFP1 | |
| SCHEMBL5122789 | 0.86 | P2RX7 (0.54) | P2RX7RXFP1 | |
| SCHEMBL5131712 | 0.86 | P2RX7 (0.53) | P2RX7RXFP1 | |
| SCHEMBL5131751 | 0.84 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL1802127 | 0.83 | P2RX7 (0.82) | P2RX7 | |
| Hydrochloric Acid SCHEMBL3839613 | 0.82 | P2RX7 (0.81) | P2RX7 | |
| SCHEMBL491858 | 0.81 | P2RX7 (0.71) | P2RX7 | |
| SCHEMBL22878864 | 0.81 | P2RX7 (0.71) | P2RX7 | |
| SCHEMBL5122822 | 0.81 | MAPT (0.49) | P2RX7RXFP1 | |
| SCHEMBL17327643 | 0.80 | P2RX7 (1.00) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | claimed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | claimed |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | P2RX7 91/4885RXFP1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.